In a mouse model of bone metastasis, systemic treatment with a neutralizing anti-CXCL10 antibody significantly reduced the migration of CXCR3-expressing cancer cells to the bone and decreased overall tumor burden [110]. This evidence concerns the gene CXCR3 and cancer.